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Development of a tool for monitoring the 
prescribing of antipsychotic medications to 
people with dementia in general practice: 




Department of general Practice, 
University College Cork, Cork, 
Ireland
Background: Despite their adverse effects, antipsychotics are frequently used to manage 
behavioral and psychological symptoms of dementia. Regular monitoring of antipsychotic 
prescribing has been shown to improve the appropriateness of prescribing. However, there is 
currently no consensus on what the components of such a monitoring tool would be.
Aim: The aim of this study was to use an expert consensus process to identify the key compo-
nents of an antipsychotic repeat prescribing tool for use with people with dementia in a general 
practice setting.
Methods: A modified eDelphi technique was employed. We invited multidisciplinary experts in 
antipsychotic prescribing to people with dementia to participate. These experts included general 
practitioners (GPs), geriatricians and old age psychiatrists. The list of statements for round 1 
was developed through a review of existing monitoring tools and international best practice 
guidelines. In the second round of the Delphi, any statement that had not reached consensus 
in the first round was presented for re-rating, with personalized feedback on the group and the 
individual’s response to the specific statement. The final round consisted of a face-to-face expert 
meeting to resolve any uncertainties from round 2.
Results: A total of 23 items were rated over two eDelphi rounds and one face-to-face consensus 
meeting to yield a total of 18 endorsed items and five rejected items. The endorsed statements 
informed the development of a structured, repeat prescribing tool for monitoring antipsychotics 
in people with dementia in primary care.
Conclusion: The development of repeat prescribing tool provides GPs with practical advice 
that is lacking in current guidelines and will help to support GPs by providing a structured 
format to use when reviewing antipsychotic prescriptions for people with dementia, ultimately 
improving patient care. The feasibility and acceptability of the tool now need to be evaluated 
in clinical practice.
Keywords: dementia, antipsychotics, prescribing, eDelphi, consensus, general practice
Introduction
Most people living with dementia will experience behavioral and psychological 
symptoms of dementia (BPSD) at some stage in the illness1 with some studies estimat-
ing that between 80% and 90% of people with dementia will experience at least one 
symptom of BPSD.2 BPSD encompasses a wide range of noncognitive symptoms that 
affect people living with dementia and includes behaviors such as agitation or aggres-
sion and psychological symptoms such as anxiety or hallucinations. BPSD is associated 
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with increased rates of admission to nursing homes3 and 
longer in-patient hospital stays4 and is a major contributor to 
caregiver stress and depression.5 General practitioners (GPs) 
play a pivotal role in the care of people with dementia,6,7 pro-
viding the day-to-day medical care for people with dementia 
living in their own homes and in nursing homes. However, 
similar to their secondary care colleagues,8 GPs can find the 
management of BPSD a particularly challenging aspect of 
dementia care.9,10 Non-pharmacological strategies are rec-
ommended as first-line treatment in BPSD.11 Personalized 
non-pharmacological interventions such as personalized 
music therapy12,13 and formal caregiver training to enhance 
communication skills13 may have a role in the management 
of BPSD; however, the uptake of non-pharmacological 
strategies is low.14 Psychotropic medication, in particular 
antipsychotics, are frequently employed to manage BPSD;14 
however, antipsychotics are not recommended unless there 
is a serious risk of harm to the person with dementia or 
others.11 Antipsychotics have particular adverse effects in 
people with dementia including an increased risk of stroke 
and increased mortality.15,16 Furthermore, evidence suggests 
that antipsychotics are, at best, only minimally effective 
at improving BPSD.15,17 Despite their adverse effects and 
minimal effectiveness, antipsychotics are still prescribed to 
people with dementia experiencing BPSD.18,19 The rates of 
antipsychotic prescribing in people with dementia vary from 
country to country with rates as high as 29% in a 2013 audit 
conducted in Ireland20 and lower rates of 17.7% in a compa-
rable 2012 audit in the UK.21 Nursing home residents, who 
typically have more advanced dementia, are significantly 
more likely to be on an antipsychotic medication than people 
with dementia living in their own homes,20 up to five times 
as likely in one study.19
The reason for continued prescribing of these potentially 
harmful medications is complex.22 In the context of stretched 
resources, non-pharmacological alternatives to antipsychotic 
prescribing can be viewed as being impractical and not 
implementable.23 The benefit of antipsychotic medication can 
be overestimated.24 Furthermore, both GPs and consultant 
psychiatrists report that they sometimes feel under pressure 
from nursing home staff, and occasionally family caregivers, 
to prescribe medications.8,10 As a result, antipsychotics are 
sometimes employed to enable the person with dementia, 
their caregiver and the nursing home staff to cope with these 
behaviors and symptoms.22
When prescribed for BPSD, antipsychotics should only 
be used on a short-term basis and should be reviewed for 
side effects and for effectiveness as many of the harmful side 
effects of antipsychotics are dose and duration dependent. 
However, there is evidence that antipsychotics are often 
inappropriately prescribed to people with dementia for pro-
longed periods of time,18 sometimes without a documented 
indication25 and with suboptimal review processes.26 A 
systematic review in 2014 examined interventions to reduce 
inappropriate prescribing of antipsychotic medications in 
care homes and identified a wide variety of interventions from 
educational interventions to organizational changes.27 Medi-
cation review was identified as an intervention employed 
to reduce antipsychotic prescribing with some promising 
results.27 Since that 2014 review, other studies have shown 
that regular monitoring of antipsychotic prescribing can 
reduce the overall prescribing of antipsychotics in demen-
tia28 and improve the appropriateness of prescribing.29 The 
WHELD study identified the value of antipsychotic review, 
demonstrating that it can lead to a 50% reduction in antip-
sychotic use in nursing homes.28 However, it is also high-
lighted that to positively benefit the person with dementia 
any intervention to reduce antipsychotic medication needs 
to be supported by non-pharmacological interventions such 
as social interaction.28
A recent qualitative study conducted by the authors 
explored the challenges GPs experience managing BPSD.10 
In the study participating GPs called for GP-specific 
guidance on the pharmacological management of BPSD. 
Guidance for GPs in the form of a repeat prescribing tool 
to monitor the prescribing of antipsychotics in dementia 
would facilitate the conduct of antipsychotic reviews in 
general practice. However, there is currently no consensus 
on what the components of such a tool would be.
The aim of this study was to use an expert consensus 
process to identify the key components of an antipsychotic 
repeat prescribing tool for use with people with dementia in 
a general practice setting.
Methods
study design
A Delphi method was used to establish expert consensus 
that would inform the development of a repeat prescribing 
tool for GPs to use when monitoring people with dementia 
on antipsychotic medications. The Delphi is a “group 
facilitation technique that seeks to obtain consensus on the 
opinions of experts through a series of structured question-
naires” (known as rounds).30 The key features of the Delphi 
method include the following: recruiting relevant experts 
for the study, compiling questionnaires with a list of state-
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Development of an antipsychotic repeat prescribing tool
results, giving anonymized feedback to participants about 
how their responses compared to the rest of the group and 
giving participants the opportunity to revise their responses 
to the questionnaire in light of this feedback.31 This iterative 
process continues over multiple rounds of questionnaires 
until consensus is reached, with some statistical criterion 
being used to define consensus. A modified Delphi was 
employed in this study, which combines the questionnaire 
with a physical meeting of experts to discuss the results.32 
This face-to-face meeting is recommended at the end of the 
last round to exchange views and resolve uncertainties and 
is, therefore, often considered to function as a final “round”.32 
We utilized a web-based platform to organize and facilitate 
communication. This eDelphi approach has practical advan-
tages over the traditional paper-based Delphi model facilitat-
ing the participation of experts from different geographical 
locations and enabling faster response times.33
research steering group
The research team formed a research steering group. This 
consisted of the research facilitator (NG) and two GPs (TF, 
AAJ) both of whom have clinical and research expertise in the 
management of BPSD. The function of this working group 
was to review the literature to inform the development of the 
first round of the questionnaire and to participate in a final 
meeting once the eDelphi rounds were completed to discuss 
any uncertainties. The members of the research steering 
group did not complete the eDelphi questionnaires.
selection and recruitment to the 
expert panel
Participants in the Delphi were purposively selected by the 
research team based on their known expertise in the area.30 
To ensure diversity, a panel of medical experts was recruited 
from different medical specialities to participate in the Delphi 
consensus. Medical professionals participating in the eDelphi 
included GPs, old age psychiatrists and geriatricians.
GPs were eligible to participate if they met the follow-
ing inclusion criteria: minimum of 10 years as a practicing 
GP, regularly engaged in the management of patients with 
BPSD and providing care to people with dementia in a nurs-
ing home setting. GPs meeting these inclusion criteria were 
identified nationally. From this population, a sample of GPs 
was purposively selected to include GPs of different ages and 
with different practice locations (rural/urban) with the goal 
of achieving maximum variation. Consultant psychiatrists 
and consultant geriatricians were eligible to participate in 
the study if they provided care to people with BPSD in a 
nursing home setting and if they had a research interest in 
this area with relevant peer-reviewed publications. Once 
eligible participants were identified, they were individually 
emailed, provided with information on the study and invited 
to participate in the eDelphi.
Questionnaire development
The questionnaire was iteratively developed by the research 
steering group. The content of the questionnaire was informed 
by a review of existing antipsychotic drug-monitoring tem-
plates from the UK and Canada34–36 and by a review of inter-
national guidance documents on antipsychotic prescribing 
in dementia.37–41
Analysis of rounds and consensus criteria
We asked the participants to state the extent to which they 
agreed with a list of statements using a 5-point Likert scale. 
The option to provide free text comments was provided 
throughout the questionnaire. The level of percentage 
agreement necessary to reach consensus for this particular 
study was informed by the literature on consensus crite-
rion in Delphi processes42 and by Delphi studies explor-
ing similar research areas.43–45 In cases where a statement 
received 80% agreement, it was agreed that consensus 
had been reached. These statements were omitted from 
further rounds and were automatically included in the 
monitoring template. Any statement receiving 40% was 
rejected and, therefore, excluded from the monitoring 
template. All statements that fell between 40% and 79% 
agreement were deemed undecided, ie, had not reached 
consensus, so these statements were carried forward into 
the next round to be re-rated.
In the second round of the eDelphi, any statements that 
had not reached consensus in the first round were presented 
for re-rating using the same 5-point Likert scale. In this round, 
each participant was provided with individualized feedback 
which included the mean answer of the group response to 
each statement in round 1. In addition, the participant’s 
own response to the statements in round 1 was provided to 
illustrate their position in the group. This offered Delphi 
members an opportunity to revise and refine initial answers 
based on the group opinion. Free text comments provided 
by participants in round 1 were also included as statements 
in round 2 if the same suggestion was made by two or more 
participants. For each statement in the second round, it was 
decided that 70% agreement reached consensus to include 
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Ethical approval was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals. Participants 
were advised in an information sheet and in the initial e-mail 
they received, that the completion of the first round of the 




A total of 17 medical professionals with expertise in dementia 
care were invited to participate, and 14 agreed to participate 
in the study. This group of 14 experts included the following: 
eight GPs, four old age psychiatrists and two geriatricians 
(the breakdown of the retention rate for each professional 
group is provided in Table 1).
Item ratings
A total of 23 items were rated over two rounds to yield a 
total of 18 endorsed items and five rejected items. Table 2 
summarizes the number of items rated, endorsed and rejected 
over the two eDelphi rounds.
round 1 questionnaire results
The first-round questionnaire consisted of 21 statements, and 
participants were asked to rate the statements using a 5-point 
Likert scale (Table 3). Surveys were open for completion 
for 2 weeks. Nine of the statements reached consensus and 
were endorsed in round 1. These statements were, therefore, 
included in the monitoring template and were excluded 
from the second-round survey. One statement received only 
28.5% agreement, which was below the cutoff of 40%, so 
this statement was automatically excluded from the monitor-
ing template and from any further rounds of questionnaire. 
Eleven statements did not reach consensus, rating between 
40% and 79%; therefore, all these statements were included 
in round 2 for re-rating. All statements that were endorsed, 
rejected or did not reach consensus in round 1 are presented 
in Table 3.
Qualitative feedback provided by participants in the free 
text comment boxes of round 1 was thematically analyzed. 
If a suggestion was made by two or more participants, it was 
included in the questionnaire for round 2. One suggestion 
made by two participants was that urinalysis or mid-stream 
urine (MSU) should be done as a baseline test prior to initia-
tion of antipsychotic medication.
“… urinalysis should be a standard baseline test +/-MSU…” 
[old age psychiatrist 1]
“I would also do an MSU” [GP 1]
As a result of these comments, a statement on per-
forming MSU analysis was included in the second-round 
questionnaire.
Another item that received several qualitative comments 
was the statement that recommended medical review should 
happen 6 weeks after the antipsychotic medication was com-
menced. Three participants suggested that medical review 
should occur earlier than this:
“Earlier initial review may be more appropriate, eg, 
2–4 weeks” [old age psychiatrist 1]
“Should be reviewed within a month” [geriatrician 2]
“Review should be earlier than 6 weeks” [old age psy-
chiatrist 2]
As a result of these comments, an additional statement 
was included in the questionnaire for round 2 stating that 
review should occur at 4 weeks. Even though the original 
statement that a review should occur at 6 weeks did achieve 
consensus in round 1, in light of the qualitative feedback, 
the research steering group decided to include the original 
statement again in the questionnaire for round 2.
The wording of one of the statements was modified 
based on the qualitative feedback provided by participants. 
The modified item was related to conducting a body mass 
index (BMI) measurement. Initially, the statement in the 
Delphi questionnaire was “The presence/absence of the 
following medication side-effects should be documented 
prior to repeat prescribing of antipsychotics in patients with 
dementia … increase in BMI”. This rating did not reach 
consensus in round 1, and concerns were raised about the 
practicality of measuring the BMI:
“BMI risk would not be high up my decision-making pro-
cess given the typical patient profile…” [geriatrician 1]
“It would not be easy to weigh and measure a patient in a 
family home setting” [GP 2]







gPs 8 8 7
Psychiatrists 4 4 2
geriatricians 2 2 2
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Development of an antipsychotic repeat prescribing tool
Table 2 statements that were accepted, rejected and re-rated at each stage
Number of 
statements







round 1 21 11 1 9 2
round 2 11 9 2 2a 0
Note: aTwo statements brought to research steering group for discussion were ultimately rejected.
Table 3 round 1 statements with their associated consensus decisions
Statement Agreement  
rating (%)
Outcome
A repeat prescribing monitoring template for antipsychotic (AP) use in patients with dementia 
should include personal details including name, date of birth and patient identification number
92.8 endorsed
A repeat prescribing monitoring template for AP use in patients with dementia should  
include clearly stated medical diagnosis
92.8 endorsed
A repeat prescribing monitoring template for AP use in patients with dementia should 
include the name, dose and duration of AP drug prescribed
92.8 endorsed
A repeat prescribing monitoring template for AP use in patients with dementia should  
include whether or not additional Prn (as required) APs were used during the period of AP 
prescription
100 endorsed
Medical review prior to initiation of APs for patients with dementia should include  
documented consent from patient with dementia/patient’s next of kin prior to initiation  
of drug therapy
28.5 rejected
Medical review prior to initiation of APs for patients with dementia should include trial  
of non-pharmacological treatment options prior to initiation of AP drug therapy
92.8 endorsed
Prior to initiation of AP drug therapy by gPs, in patients with dementia, the following  
should be checked and documented
1. Baseline FBC 78.5 no consensus
2. Baseline lFTs 64.2 no consensus
3. Baseline TFTs 78.5 no consensus
4. Baseline U&es 78.5 no consensus
5. Baseline BMI 64.2 no consensus
6. Baseline eCg 78.5 no consensus
Adverse drug reactions – gPs should document improvements/disimprovements in  
BPsD following a period of AP use
100 endorsed
The presence/absence of the following medication side effects should be documented 
prior to repeat prescribing of APs in patients with dementia:
1. Increase in BMI 71.4 no consensus
2. Cardiovascular disease/worsening of condition in patients with preexisting  
cardiovascular disease
78.5 no consensus
3. sedation 100 endorsed
4. extrapyramidal symptoms/impaired mobility 100 endorsed
5. Confusion 92.8 endorsed
regarding review of AP prescription for patients with dementia:
1. Patients with dementia who are prescribed AP drugs in the community for the first  
time should have a documented review by their gP at 6 weeks
85.7 Divided opinion in  
qualitative feedback
2. Following the initial 6-week review, patients with dementia on AP therapy should have  
documented review by their gP at least 3 monthly thereafter
85.7 endorsed
3. Medical reasons for continuation/discontinuation of the drug should be documented  
by the gP at each review
85.7 endorsed
Abbreviations: AP, antipsychotic; BMI, body mass index; eCg, electrocardiograph; FBC, full blood count; gP, general practitioner; lFTs, liver function tests; TFTs, thyroid 
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As a result, this question was modified to include the 
stem “where feasible” and was included in the second-round 
questionnaire for re-rating.
Finally, concern was raised as to the feasibility of per-
forming an electrocardiograph (ECG) prior to commencing 
an antipsychotic:
“… Re ECG, this is very relevant, but not always 
possible – again, I do not do this routinely myself. And 
would you hold down a psychotic patient to do an ECG?” 
[geriatrician 1]
“… A baseline ECG could be difficult in a home set-
ting” [GP 1]
This statement had not achieved consensus in round 1 
(78.5% agreement), so it was included in the second-round 
questionnaire. In addition, these qualitative comments 
regarding the feasibility of conducting an ECG were included 
in the individualized feedback to participants in round 2.
round 2 questionnaire results
The second-round questionnaire consisted of 13 statements: 
eleven statements that did not reach consensus in round 1 
and 2 additional statements that were included in response 
to the qualitative comments provided by participants in 
round 1. Consensus was reached on 11 of the 13 statements 
in round 2. Details on each statement included in round 2 
and the consensus outcome are given in Table 4. Nine state-
ments achieved 70% agreement, and these statements were 
included in the monitoring template. Two statements were 
rejected as they achieved 50% agreement. Two statements 
did not reach consensus in round 2, but both statements 
reached a low percentage agreement of 54%. In the context 
of the low percentage agreement for these two statements and 
in view of the fact that a third round would include just two 
statements, these two statements were brought to the Delphi 
steering group for discussion. In a modified eDelphi, such a 
face-to-face consensus meeting is often considered to be an 
additional round.32
The first statement discussed by the research steering 
group was the statement on the documentation of an increase 
in BMI prior to repeating a prescription for an antipsychotic. 
After discussion with the steering group, this statement 
was rejected. The decision to exclude the statement was 
informed by the qualitative feedback in the Delphi rounds: 
Table 4 round 2 statements with their associated consensus decisions
Statement Agreement  
rating (%)
Outcome
Prior to initiation of AP therapy by gPs in patients with dementia, the following should 
be checked:
1. FBC 90.9 endorsed
2. lFTs 90.9 endorsed
3. TFTs 90.9 endorsed
4. U&es 81.8 endorsed
5. BMI 50 rejected
6. eCg 72.7 endorsed
7. Urinalysis 50 rejected
Where feasible, the presence/absence of the following medication side effects should  
be documented prior to repeat prescribing of APs in patients with dementia:
1. Increase in BMI 54 Brought for discussion in  
the research steering group
2. Cardiovascular disease/worsening of condition in patients with preexisting 
cardiovascular disease
72.7 endorsed
In a monitoring template for repeat prescribing of APs in patients with dementia:
1. Patients with dementia who are prescribed AP drugs for the first time should have  
a documented review by their gPs within 6 weeks
72.7 endorsed
2. Following initial review, patients with dementia on repeat prescribed that AP therapy  
should have a documented review by their gPs at least 3 monthly thereafter
72.7 endorsed
3. Medical reasons for continuation/discontinuation of the drug should be documented  
by the gPs at each review
81.8 endorsed
4. Patients with dementia who are prescribed AP drugs for the first time should have  
a documented review by their gPs within 4 weeks
54.5 Brought for discussion in  
the research steering group
Abbreviations: AP, antipsychotic; BMI, body mass index; eCg, electrocardiograph; FBC, full blood count; gP, general practitioner; lFTs, liver function tests; TFTs, thyroid 
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Development of an antipsychotic repeat prescribing tool
a low percentage agreement of 54% in round 2 and a 17.4% 
reduction in percentage agreement from the first round to the 
second round. The second statement discussed at the meeting 
was the statement that after initiation of an antipsychotic, a 
patient should have a documented review by their GP within 
4 weeks. This statement was added to round 2 after consid-
eration of the qualitative feedback from round 1; however, 
it received only a 54% agreement rating in round 2. The 
conflicting statement, recommending review at 6 weeks, was 
endorsed in both round 1 and round 2 of the eDelphi. In this 
context, it was decided to reject this statement that review 
should occur within 4 weeks in favor of the statement that 
review should occur at 6 weeks.
The combined consensus from round 1 and round 2 
resulted in 18 statements that were endorsed by the expert 
panel. These 18 statements informed the content of an 
antipsychotic repeat prescribing tool for GPs to use when 
monitoring people with dementia on antipsychotics. The 
final tool was developed by the Delphi steering group as 
shown in Figure S1.
Discussion
This study utilized a modified eDelphi expert consensus 
process to inform the development of an antipsychotic repeat 
prescribing tool in people with dementia in a general practice 
setting. This repeat prescribing tool will provide GPs with 
a practical, relevant and implementable resource that will 
support them in monitoring their patients with dementia on 
antipsychotic medications.
A number of key issues regarding the challenges of 
monitoring antipsychotic prescribing in dementia were 
identified including the use of ECG, measurement of BMI 
and the scheduled time for the review of prescribing. The 
practical difficulties in obtaining an ECG prior to initiation 
of antipsychotic medication were highlighted by several 
participants in the qualitative feedback; however, it did 
ultimately achieve consensus in round 2 and was, therefore, 
included in the final tool. International guidelines do not 
specifically recommend performing an ECG;37,38,41 however, 
given the propensity of nearly all antipsychotic medication 
to cause QT prolongation, it is a reasonable consideration, 
where practical, in advance of initiating these medications. 
Likewise, although BMI measurement is not recommended 
in the existing guidelines,37,38,41 it was included as a statement 
for review in the eDelphi as antipsychotics are known to 
result in weight gain.46 However, the difficulties in measuring 
BMI prior to initiation of an antipsychotic were highlighted 
by several participants, and this statement was eventually 
rejected in round 2.
One particularly contentious issue was the recommended 
time interval after an initial prescription for an antipsychotic 
during which a GP review of the effect of the medication 
should be undertaken, with some participants advocating for 
a review within 4 weeks instead of 6 weeks. However, the 
statement that a review should occur within 6 weeks was the 
statement that was ultimately endorsed. The existing guide-
lines do vary on this issue of when a review should occur 
after initiation of an antipsychotic medication in a person 
with dementia. For instance, the most recent 2018 National 
Institute for Clinical Evidence guidelines on dementia care 
recommend that initial treatment with an antipsychotic should 
use the lowest effective dose for the shortest time with a 
reassessment of the person at least every 6 weeks.47 This 
is echoed in the American Psychiatric Association (APA) 
2016 guidelines on antipsychotic medications in dementia 
which recommends a review of symptoms 4–6 weeks after 
initiation of an antipsychotic.38 Guidance from Australia 
recommends that if there is no treatment efficacy within a 
relatively short timeframe (eg, 1–2 weeks), treatment should 
be discontinued.41 Overall, in the different guidance docu-
ments, the recommended time between medication initiation 
and GP review of the effect of the medication ranges from 2 to 
6 weeks. The different guidance documents do not distinguish 
between a person with dementia living at home from a person 
with dementia living in a nursing home setting. However, in 
a nursing home setting, residents are being observed by the 
nursing home staff; therefore, a GP review at 6 weeks may be 
acceptable. It is likely, however, that a person with dementia 
living at home would benefit from an earlier review.
One finding that was overwhelmingly rejected in round 1 
was the statement that “medical review prior to initiation 
of antipsychotics for patients with dementia should include 
documented consent from patient with dementia/patient’s 
next of kin prior to initiation of drug therapy”. This statement 
was included in the original questionnaire for round 1 as 
both the NICE guidance and the APA guidance recommend 
discussing the benefits and potential harms with the person 
and their family members or carer prior to commencing an 
antipsychotic. The practical challenges of obtaining “docu-
mented consent” may have influenced the rejection of this 
statement, rather than a reluctance on the part of participants 
to discuss the risks and benefits with the person with dementia 
or their caregiver. Antipsychotics should only be prescribed 
if the person with dementia is a danger to either themselves or 
to others.11 In these situations, it may not always be possible 
to obtain documented consent from either the person with 
dementia, who may not be able to give informed consent, or 


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Comparison with existing literature
The Delphi consensus approach has been used successfully 
to develop criteria for potentially inappropriate medication 
in people nearing the end of life.48 More specifically, Delphi 
studies have been used previously to address the issue of 
potentially inappropriate prescribing of medication to people 
with dementia.49–54 However, we are unaware of any existing 
literature that used a consensus development method to inform 
the development of an antipsychotic repeat prescribing tool for 
use in people with dementia. Previously, a modified eDelphi 
consensus procedure was used to develop practice guidelines 
on the prescription of antipsychotics to people with dementia 
living in care homes.55 The majority of clinicians participating 
in that expert panel were old age psychiatrists; however, the 
views of geriatricians and GPs were incorporated. Although 
the study did not develop a repeat prescribing tool it did 
address certain issues surrounding antipsychotic initiation and 
review. The results largely echoed our study results, however, 
there were some notable differences. These differences cen-
tered on the consensus reached on the consultation that should 
take place with family caregivers and on conducting ECGs 
prior to initiating antipsychotic medication. First, the study 
recommended that ECG was only necessary in patients with 
a history of cardiovascular disease or if the patient was on 
another medication that can prolong the QT interval. Second, 
the study affirmed that the patient (if appropriate) and the 
primary family caregiver should be consulted in the critical 
phases of treatment, specifying that they should be consulted 
pre treatment with an antipsychotic. The study did not discuss 
what the time interval should be between antipsychotic initia-
tion and review; however, it does state that if there is a lack of 
improvement, the dose should be increased until side effects 
appear and continued for a period of 4 weeks.
strengths and limitations
A Delphi method was chosen in this study as it is particu-
larly appropriate when developing consensus when existing 
evidence is insufficient. Other methods of consensus devel-
opment, such as nominal group technique, were not feasible 
as the experts participating in the consensus development 
worked in different geographical regions. Another strength 
of choosing the Delphi technique is that of quasi-anonymity42 
although the participants are known to the researcher, the 
participants remain anonymous to each other, preserving 
independent opinion. The multidisciplinary nature of the 
Delphi participants offered the opportunity to consider the 
different views of clinicians involved in the care of people 
with BPSD and enriched the results.
A limitation of this study is the small number of Delphi 
participants, with only 14 members. However, as little as 
ten members have been reported to yield strong evidence 
in Delphi studies.56 Another limitation is the relatively high 
dropout rate of 21.4% after three members dropped out of 
the study in round 2. However, despite this dropout, the 
response rate remained above 70% for each round, which is 
the recommended response level to yield robust results.57 We 
did not, therefore, follow-up with nonresponders. The choice 
of methodology prevented in-depth discussion among the 
expert participants; however, the ability to provide in-depth 
qualitative feedback allowed for the sharing of ideas. In addi-
tion, the existence of the research steering group facilitated 
in-depth discussion on selected topics as required. As the 
content for this eDelphi was quite clinical in nature, the deci-
sion was made to not include people living with dementia or 
their caregivers in the initial eDelphi process. However, an 
important next step would be to get the input of people living 
with dementia, their caregivers and nursing home staff prior to 
implementation of the monitoring tool in a clinical setting.
Implications for future research
The existence of a repeat prescribing tool for monitoring 
antipsychotic prescribing in general practice will not in 
itself guarantee that monitoring will occur. The feasibility 
and acceptability of the tool need to be evaluated in clinical 
practice. This phase will involve all relevant stakeholders 
including people with dementia, their caregivers, nursing 
home staff and community pharmacists.
This tool needs to be evaluated to identify whether imple-
mentation of the tool leads to more frequent reviews and more 
appropriate prescribing and de-prescribing of antipsychotics 
in people living with dementia. Future research then needs to 
focus on incorporating this antipsychotic repeat prescribing 
tool into a wider intervention that addresses all the barriers to 
conducting antipsychotic reviews in people with dementia in 
a general practice setting. These challenges can include a lack 
of knowledge on the part of some GPs of the adverse effects 
of antipsychotics in dementia and an overestimation of their 
benefits in BPSD.58,59 This can lead to a lack of motivation 
to monitor prescribing on the part of the GP – why monitor 
if you do not intend to stop the medication? In addition to 
highlighting the value of monitoring antipsychotics, GPs need 
to be further supported by practical advice on how to conduct 
an antipsychotic review and how to gradually taper antip-
sychotic medications. This repeat monitoring tool provides 
general prescribing guidance to GPs monitoring patients with 
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Development of an antipsychotic repeat prescribing tool
be assessed and managed at an individual level in accordance 
with their comorbidities and risk factors. The tool developed 
here is intended as an educational device as well as a practi-
cal tool. Further GP-relevant guidelines on antipsychotic 
prescribing would support GPs in conducting this task.10
Conclusion
Through an expert consensus process, we developed a 
repeat prescribing tool for use by GPs when initiating and 
monitoring antipsychotic medications prescribed to people 
living with dementia in the community or in a nursing home 
setting. This tool provides GPs with practical advice that can 
be lacking in current guidelines and provides an additional 
level of detail to GPs to aid clinical decision-making. This 
tool will help to support GPs by providing a structured format 
to use when reviewing antipsychotic prescriptions in people 
with dementia, ultimately improving patient care.
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Development of an antipsychotic repeat prescribing tool
Repeat Prescribing Monitoring Template for Antipsychotic Drug
Treatment in Patients with Dementia (For use byGeneral Practitioners)
Personal Details
Name: ______________________
Date of Birth: _________________
Patient MRN: _________________





Details of Antipsychotic Drug
Drug Name: _____________________ Dose: __________________
Mode of delivery: _________________ Frequency: _____________
Date of initial prescription: ___________________________________
Indication for initial prescription: _______________________________
________________________________________________________
PRN antipsychotic medication required: YES NO





The following adverse drug reactions are/have been experienced by the patient since initiation of antipsychotic drug:
Confusion 
Following prescription of antipsychotic drug, has patient’s BPSD improved or, worsened 
2. Sedation 
3. Extra-pyramidalsymptoms/impaired mobility 
1. Cardiovascular disease/worsening of condition in patients with pre-existing cardiovascular disease 
Reasons for continuation of antipsychotic drug (where applicable): ______________________________________
___________________________________________________________________________________________
This patient will be medically reviewed at 6 weeks and 3 monthly thereafter 
Print Name: _____________________________ MCRN: _____________________________________
Date: ______________________________________Signature: ______________________________
Antipsychotic drug treatment will be continued Antipsychotic drug treatment will be discontinued 
Review Prior to initiation of antipsychotic drug therapy
Trial of non-pharmacological treatment options prior to initiation of antipsychotic YES NO 
Details of above: ____________________________________________________________________________
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